-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Neutral on Zentalis Pharma, Maintains $4 Price Target

Benzinga·03/28/2025 13:51:23
Listen to the news
Wedbush analyst Robert Driscoll reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Neutral and maintains $4 price target.